A review of Vilazodone, Serotonin, and Major Depressive Disorder

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 16, Issue 1, 2014, Pages

  Pierz, Kerri A ^a   Thase, Michael E ^b  

^a Clinical Data Inc   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PINDOLOL; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2B RECEPTOR; SERTRALINE; VILAZODONE; ZIMELDINE;

ANTIDEPRESSANT ACTIVITY; CENTRAL NERVOUS SYSTEM; CLINICAL PRACTICE; DRUG APPROVAL; HUMAN; INCIDENCE; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION;

EID: 84897953381     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.13r01554     Document Type: Review

References (82)

1. Kessler RC, Birnbaum H, Bromet E, et al. Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R). Psychol Med. 2010;40(2):225-237. PubMed doi:10.1017/S0033291709990213.
2. Hirschfeld RM. The epidemiology of depression and the evolution of treatment. J Clin Psychiatry. 2012;73(suppl 1):5-9. PubMed doi:10.4088/JCP.11096su1c.01.
3. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196. PubMed doi:10.1016/S0140-6736(12)61729-2.
4. Stafford RS, Ausiello JC, Misra B, et al. National patterns of depression treatment in primary care. Prim Care Companion J Clin Psychiatry. 2000;2(6):211-216. PubMed doi:10.4088/PCC.v02n0603.
5. Unützer J, Park M. Strategies to improve the management of depression in primary care. Prim Care. 2012;39(2):415-431. PubMed doi:10.1016/j.pop.2012.03.010.
6. Wang PS, Demler O, Olfson M, et al. Changing profiles of service sectors used for mental health care in the United States. Am J Psychiatry. 2006;163(7):1187-1198. PubMed doi:10.1176/appi.ajp.163.7.1187.
7. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277(4):333-340. PubMed doi:10.1001/jama.1997.03540280071036.
8. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22-27. PubMed doi:10.4088/PCC.v03n0105.
9. Remick RA, Froese C, Keller FD. Common side effects associated with monoamine oxidase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(3-4):497-504. PubMed doi:10.1016/0278-5846(89)90137-1.
10. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med. 2010;77(12):859-882. PubMed doi:10.3949/ccjm.77a.09103.
11. Flockhart DA. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. J Clin Psychiatry. 2012;73(suppl 1):17-24. PubMed doi:10.4088/JCP.11096su1c.03.
12. Mark TL, Levit KR, Buck JA. Datapoints: psychotropic drug prescriptions by medical specialty. Psychiatr Serv. 2009;60(9):1167. PubMed doi:10.1176/appi.ps.60.9.1167.
13. Blier P, Saint-André E, Hébert C, et al. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol. 2007;10(1):41-50. PubMed doi:10.1017/S1461145705006395.
14. Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10(9):732-747. PubMed.
15. Thase ME. Are SNRIs more effective than SSRIs? a review of the current state of the controversy. Psychopharmacol Bull. 2008;41(2):58-85. PubMed.
16. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734-750. PubMed doi:10.7326/0003-4819-149-10-200811180-00008.
17. Gaynes BN, Dusetzina SB, Ellis AR, et al. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol. 2012;32(1):114-119. PubMed doi:10.1097/JCP.0b013e31823f705d.
18. Kornstein SG, Li D, Mao Y, et al. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. CNS Spectr. 2009;14(6):326-333. PubMed.
19. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin. 2009;25(1):161-175. PubMed doi:10.1185/03007990802622726.
20. Frampton JE. Vilazodone: in major depressive disorder. CNS Drugs. 2011;25(7):615-627. PubMed doi:10.2165/11207550-000000000-00000.
21. Coppen A. The biochemistry of affective disorders. Br J Psychiatry. 1967;113(504):1237-1264. PubMed doi:10.1192/bjp.113.504.1237.
22. Coppen A, Shaw DM, Malleson A, et al. Tryptamine metabolism in depression. Br J Psychiatry. 1965;111(479):993-998. PubMed doi:10.1192/bjp.111.479.993.
23. Prange AJ Jr. The pharmacology and biochemistry of depression. Dis Nerv Syst. 1964;25:217-221. PubMed.
24. Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry. 2004;65(suppl 4):5-10. PubMed.
25. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51(3):215-235. PubMed doi:10.1016/S0165-0327(98)00221-3.
26. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60(1):355-366. PubMed doi:10.1146/annurev.med.60.042307.110802.
27. Eisch AJ, Petrik D. Depression and hippocampal neurogenesis: a road to remission? Science. 2012;338(6103):72-75. PubMed doi:10.1126/science.1222941.
28. Carr GV, Lucki I. The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology (Berl). 2011;213(2-3):265-287. PubMed doi:10.1007/s00213-010-2097-z.
29. Pytliak M, Vargová V, Mechírová V, et al. Serotonin receptors-from molecular biology to clinical applications. Physiol Res. 2011;60(1):15-25. PubMed.
30. McDevitt RA, Neumaier JF. Regulation of dorsal raphe nucleus function by serotonin autoreceptors: a behavioral perspective. J Chem Neuroanat. 2011;41(4):234-246. PubMed doi:10.1016/j.jchemneu.2011.05.001.
31. Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol. 2009;88(1):17-31. PubMed doi:10.1016/j.pneurobio.2009.01.009.
32. Drevets WC, Thase ME, Moses-Kolko EL, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol. 2007;34(7):865-877. PubMed doi:10.1016/j.nucmedbio.2007.06.008.
33. Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin 1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57(2):174-180. PubMed doi:10.1001/archpsyc.57.2.174.
34. Stahl S. 5-HT1A receptors and pharmacotherapy: is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull. 1994;30(1):39-43. PubMed.
35. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53(3):193-203. PubMed doi:10.1016/S0006-3223(02)01643-8.
36. Blier P, de Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry. 1998;44(5):313-323. PubMed doi:10.1016/S0006-3223(98)00114-0.
37. Celada P, Puig M, Amargós-Bosch M, et al. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29(4):252-265. PubMed.
38. Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry. 2001;62(suppl 15):12-17. PubMed.
39. Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets. 2006;7(2):139-147. PubMed doi:10.2174/138945006775515446.
40. Martiny K, Lunde M, Bech P, et al. A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression. Nord J Psychiatry. 2012;66(3):147-154. PubMed doi:10.3109/08039488.2012.674553.
41. Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011;72(4):441-447. PubMed doi:10.4088/JCP.10m06596.
42. Trivedi MH, Fava M, Wisniewski SR, et al; STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252. PubMed doi:10.1056/NEJMoa052964.
43. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. Arlington, VA: American Psychiatric Association. http://psychiatryonline.org/content.aspx?bookid=28§ionid=1667485#657567. Accessed October 14, 2013.
44. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective reuptake inhibitors in severe treatment-refractory depression. S Afr Med J. 1997;87(suppl):534-537, 540. PubMed.
45. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52(5):217-220. PubMed.
46. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 1993;54(7):269-271. PubMed.
47. Appelberg BG, Syvälahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001;62(6):448-452. PubMed doi:10.4088/JCP.v62n0608.
48. Onder E, Tural U. Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. J Affect Disord. 2003;76(1-3):223-227. PubMed doi:10.1016/S0165-0327(02)00090-3.
49. Rush AJ, Fava M, Wisniewski SR, et al; STAR*D Investigators Group. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119-142. PubMed doi:10.1016/S0197-2456(03)00112-0.
50. Portella MJ, de Diego-Adeliño J, Ballesteros J, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? a randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry. 2011;72(7):962-969. PubMed doi:10.4088/JCP.09m05827blu.
51. Zanardi R, Artigas F, Franchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol. 1997;17(6):446-450. PubMed doi:10.1097/00004714-199712000-00002.
52. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial: Réseau de Recherche et d'Expérimentation Psychopharmacologique. Am J Psychiatry. 1998;155(10):1346-1351. PubMed.
53. Maes M, Libbrecht I, van Hunsel F, et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol. 1999;19(2):177-182. PubMed doi:10.1097/00004714-199904000-00014.
54. Geretsegger C, Bitterlich W, Stelzig R, et al. Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients. Eur Neuropsychopharmacol. 2008;18(2):141-146. PubMed doi:10.1016/j.euroneuro.2007.09.002.
55. Pérez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997;349(9065):1594-1597. PubMed doi:10.1016/S0140-6736(96)08007-5.
56. Portella MJ, de Diego-Adeliño J, Puigdemont D, et al. Pindolol augmentation enhances response outcomes in first depressive episodes. Eur Neuropsychopharmacol. 2009;19(7):516-519. PubMed doi:10.1016/j.euroneuro.2009.04.004.
57. Berman RM, Anand A, Cappiello A, et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry. 1999;45(9):1170-1177. PubMed doi:10.1016/S0006-3223(98)00383-7.
58. Berman RM, Darnell AM, Miller HL, et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 1997;154(1):37-43. PubMed.
59. Pérez V, Soler J, Puigdemont D, et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors: Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry. 1999;56(4):375-379. PubMed doi:10.1001/archpsyc.56.4.375.
60. Perry EB, Berman RM, Sanacora G, et al. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. J Clin Psychiatry. 2004;65(2):238-243. PubMed doi:10.4088/JCP.v65n0215.
61. Segrave R, Nathan PJ. Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum Psychopharmacol. 2005;20(3):163-174. PubMed doi:10.1002/hup.672.
62. Ballesteros J, Callado LF. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord. 2004;79(1-3):137-147. PubMed doi:10.1016/S0165-0327(02)00404-4.
63. Whale R, Terao T, Cowen P, et al. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol. 2010;24(4):513-520. PubMed doi:10.1177/0269881108097714.
64. Viibryd [package insert]. St Louis, MO: Forest Pharmaceuticals Inc; 2012.
65. Ashby CR Jr, Kehne JH, Bartoszyk GD, et al. Electrophysiological evidence for rapid 5-HT1A autoreceptor inhibition by vilazodone, a 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor. Eur J Pharmacol. 2013;714(1-3):359-365. PubMed doi:10.1016/j.ejphar.2013.07.014.
66. Page ME, Cryan JF, Sullivan A, et al. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002;302(3):1220-1227. PubMed doi:10.1124/jpet.102.034280.
67. Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol. 2005;510(1-2):49-57. PubMed doi:10.1016/j.ejphar.2005.01.018.
68. Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(3):326-333. PubMed doi:10.4088/JCP.08m04637.
69. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
70. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. PubMed doi:10.1192/bjp.134.4.382.
71. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. PubMed doi:10.1136/jnnp.23.1.56.
72. Jain R, Chen D, Edwards J, et al. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials [published online ahead of print October 31, 2013]. Curr Med Res Opin. PubMed doi:10.1185/03007995.2013.855188.
73. Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2012;66(4):356-368. PubMed doi:10.1111/j.1742-1241.2011.02885.x.
74. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357-366. PubMed doi:10.4088/JCP.v63n0414.
75. Clayton A, Kornstein S, Prakash A, et al. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med. 2007;4(4, pt 1):917-929. PubMed doi:10.1111/j.1743-6109.2007.00520.x.
76. Clayton AH, Kennedy SH, Edwards JB, et al. The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sex Med. 2013 Oct;10(10):2465-2476. PubMed doi: 10.1111/jsm.12004.
77. Norden M. Buspirone treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Depression. 1994;2(2):109-112. doi:10.1002/depr.3050020208
78. Landén M, Eriksson E, Agren H, et al. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999;19(3):268-271. PubMed doi:10.1097/00004714-199906000-00012.
79. Michelson D, Bancroft J, Targum S, et al. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry. 2000;157(2):239-243. PubMed doi:10.1176/appi.ajp.157.2.239.
80. Othmer E, Othmer SC. Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. J Clin Psychiatry. 1987;48(5):201-203. PubMed.
81. Laughren TP, Gobburu J, Temple RJ, et al. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry. 2011;72(9):1166-1173. PubMed doi:10.4088/JCP.11r06984.
82. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342-351. PubMed doi:10.1176/appi.ajp.2007.06111868.